Join to View Full Profile
200 1st St SwRochester, MN 55905
Phone+1 507-284-2511
Are you Dr. Afif?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 7 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Waqqas Afif, MD is a gastroenterologist in Rochester, Minnesota. He is affiliated with Mayo Clinic Hospital - Rochester.
Clinical Trials
- TDM Guided Early Optimization of ADAL in Crohn's Disease Start of enrollment: 2017 Jan 17
Publications & Presentations
PubMed
- Treatment patterns for advanced therapies in Canadians with moderate-to-severe inflammatory bowel disease: a retrospective cohort analysis.Laura Targownik, Waqqas Afif, Sunny Singh, Jesse Siffledeen, Christopher Ma
Journal of the Canadian Association of Gastroenterology. 2025-02-01 - Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data.David C Sealey, Kai Fai Ho, Z Christina Zhou, Michael Clark, Brian G Feagan
Canadian Journal of Gastroenterology & Hepatology. 2025-01-01 - Acceptability, feasibility, and impact of the MyGut digital health platform in the monitoring and management of inflammatory bowel disease.Jamie Zhen, Maude Simoneau, Pooja Sharma, Pascale Germain, Pascale Watier-Levesque
Journal of the Canadian Association of Gastroenterology. 2024-12-01
Press Mentions
New STELARA® (Ustekinumab) Long-Term Data Support Its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative ColitisMarch 4th, 2023- VIDEO: Stelara Safe, Effective for the Long-Term Treatment of Moderate to Severe UCOctober 21st, 2022
- Janssen Touts Positive Mid-Late Stage Data from Two Ulcerative Colitis TrialsOctober 10th, 2022
- Join now to see all
